FDA Issues Losartan Blood Pressure Medication Recall Over Cancer Risk

More blood pressure medication recalled due to possible cancer risk

Yet another blood pressure medication has been added to the list of recalled hypertension drugs.  

» RELATED: Blood pressure medication recalls: Everything you should know, Atlanta doctors, experts say

Mylan Pharmaceuticals has voluntarily expanded its recall for its valsartan-containing products, the U.S. Food and Drug Administration announced.

The affected pills include valsartan, amlodipine/valsartan and valsartan/hydrochlorothiazide tablets and were distributed in the United States between March 2017 and November 2018. The FDA has listed additional information about the specifics, including doses, lot numbers and expiration dates, on its site.

According to the press release, the drugs contain traces of N-nitroso-diethylamine (NDEA). The impurity, typically found in certain foods, drinking water and air pollution, has been classified as a human carcinogen by the International Agency for Research on Cancer. 

Mylan is notifying its distributors and customers by letter and is arranging for the return of all recalled products. It is also coordinating returns with retailers, wholesalers and consumers. 

Patients on the medications are advised to continue taking the tablets and to contact their doctor for advice. The company said, “the risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any comparable alternative treatment.”

The agency recently recalled several other blood pressure medications due to cancer concerns, and another was recalled for mislabeling

Read the full FDA announcement at FDA.gov.

» RELATED: Yet another blood pressure medication recalled over cancer risk

Support real journalism. Support local journalism. Subscribe to The Atlanta Journal-Constitution today. See offers.

Your subscription to the Atlanta Journal-Constitution funds in-depth reporting and investigations that keep you informed. Thank you for supporting real journalism.

Related Stories

X